Stock JANX JANUX THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Janux Therapeutics, Inc.

Equities

JANX

US47103J1051

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
53.5 USD +6.13% Intraday chart for Janux Therapeutics, Inc. +17.92% +398.60%
May. 30 Scotiabank Starts Janux Therapeutics With Sector Perform Rating MT
May. 30 Certain Pre Funded Warrants of Janux Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 30-MAY-2024. CI

Other languages

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Scotiabank Starts Janux Therapeutics With Sector Perform Rating
Certain Pre Funded Warrants of Janux Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 30-MAY-2024.
Certain Stock Options of Janux Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 30-MAY-2024.
Certain Common Stock of Janux Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 30-MAY-2024.
Wedbush Raises Janux Therapeutics' PT to $74 From $53, Keeps Outperform Rating
Janux Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
JonesTrading Starts Janux Therapeutics With Buy Rating, $70 Price Target
Sector Update: Health Care Stocks Slipping Late Afternoon
Sector Update: Health Care
Janux Therapeutics Said to be Considering Sale
Janux Therapeutics Considering Options, Including Sale, Bloomberg Reports
Janux Therapeutics Reportedly Weighs Possible Sale
BTIG Starts Janux Therapeutics With Buy Rating, $62 Price Target
Cantor Fitzgerald Starts Janux Therapeutics With Overweight Rating, $100 Price Target
H.C. Wainwright Adjusts Price Target on Janux Therapeutics to $50 From $35, Keeps Buy Rating
Janux Therapeutics Q4 Net Loss Narrows, Revenue Decreases
Janux Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Janux Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. JANX Stock
  4. News Janux Therapeutics, Inc.
  5. Other languages